Importance of the field: Cytarabine is a polar nucleoside drug used for the treatment of myeloid leukemia and non-Hodgkin's lymphoma. The drug has a short plasma half-life, low stability, and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been extensively explored to enhance the half-life, stability, and delivery of cytarabine. 
Introduction
Blood cancers such as leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and myeloma are characterized by the abnormal production of malformed lymphocytes and/or other blood cells. The cancer cells multiply without control and accumulate in bone marrow, blood and lymphatic tissues, and thus interfere with healthy cells and immune cell production and function. Ultimately these events result in blood/lymphatic disorders, such as leukemia, lymphoma, myeloma, and myelodysplastic syndromes based on affected tissue [1] .
The malformed cells are results of one or more acquired mutations in DNA of lymphatic or blood forming stem cells, which on multiplication (clone formation) generate high number of abnormal white blood cells. For example, in chronic myelogenous leukemia (CML) acquired mutation affects hematopoietic stem cells. CML is characterized by presence of Philadelphia (Ph) chromosome generated through translocation and fusion of the Abelson oncogene (ABL) at chromosome 9 and the break-point cluster region (BCR) at chromosome 22 leading to the generation of a BCR-ABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein [2] .
Leukemia, lymphoma, and myeloma are diagnosed in all ages and account for the deaths of approximately 54,000 people in United States in 2010, nearly 9.5 percent of deaths from cancer in 2010. Leukemia is a one of the most fatal hematopoietic neoplasms and represents a wide range of blood cancers mainly related to abnormal increase in the number of white blood cells (leukocytes). The death toll is expected to increase as new cases are diagnosed annually, suggesting a highly fatal nature of leukemia if unattended or untreated at early stages of development [3] . Thus, causes, diagnosis, treatment, and prognosis of leukemia are subjects of major interest. [4] .
Depending upon the type of abnormal early blast or mature cells present, leukemia can be categorized into acute or chronic forms, respectively. The acute leukemia is identified by the rapid increase of immature white blood cells that crowd and accumulate around bone marrow, and thus induce the haemopoietic organ inability to produce normal blood cells. Therefore, immediate and aggressive treatment is required in acute leukemia due to rapid progression and accumulation of the malformed cells, which with time, enter the bloodstream and invade other organs. Chronic leukemia is caused by the excessive build up of abnormal mature white blood cells, which takes time to progress [5] . Further, leukemia can be lymphoblastic or lymphocytic leukemias (LL) and myeloid or myelogenous leukemias (ML) depending upon type of blood cell affected.
The lymphoblastic or lymphocytic leukemias occur due to the cancerous modifications of bone marrow cells that are converted to lymphocytes. Lymphocytes have roles as the infection-fighting immune system cells. The myeloid or myelogenous leukemias result from the cancerous change of marrow cell that form red blood cells, platelets, and white blood cells [6, 7] .
Owing to the heterogeneity of leukemia, treatment options for different classes of leukemias vary. The leukemia chemotherapy involves drugs from different classes ranging from kinase inhibitors to DNA synthesis inhibitors [8] . In many cases, a combination of two or more drugs is administered to patients to manage leukemia [9, 10] . Radiotherapy is sometimes used along with chemotherapy in some types and stages of blood cancer, such as acute lymphocytic leukemia (ALL) and B-Cell lymphomas [11, 12] .
Cytarabine (4-amino-1-β-D-arabinofuranosyl-2-(1H)-pyrimidinone, 1-β-Darabinofuranosylcytosine, araC, Cytosar-U) is a pyrimidine nucleoside-based anticancer drug ( Figure 1 ) with arabinose sugar widely used for the treatment of leukemia.
Cytarabine is predominantly used against acute myelogenous leukemia (AML) and nonHodgkin's lymphoma (NHL), chronic myelocytic leukemia (blast phase), ALL and erythroleukemia [13, 14] . It may be used alone or in combination with other anticancer agents, such as daunorubicin, doxorubicin, thioguanine, or vincristine.
When cytarabine is used in combination with other anticancer drugs for the treatment of different leukemias and solid tumors [15, 16] , the drug combinations generally improve the cancer therapy by synergistic effect [17] . Cytarabine is used in induction therapy in combination with anthracyclines and in consolidation therapy at higher dose for AML patients. The combination of cytarabine with purine nucleoside analogs, such as fludarabine and cladribine, has been extensively explored in the treatment of patients with relapsed or refractory AML [18] . In Hodgkin's disease (HD) and NHL, cytarabine is used in conjunction with other drugs using different regimens, such as DHAP (cytarabine-cisplatin-dexamethasone) [19] and ESHAP (etoposidemethylprednisolone-cytarabine-cisplatin) [20] in patients with relapsed or refractory lymphoma. Cytarabine is used as front line drug for mantle cell lymphoma (MCL) [21] .
Hyyper CVAD-MTX/Ara-c regimen (rituximab with hyperfractioned cyclophosphamide, doxorubicin, vincristine and dexamethasone plus methotrexate and cytarabine) is used for Burkitt's leukemia/lymphoma [22] and ALL [23] . Cytarabine acts on rapidly dividing cells and inhibits DNA synthesis at S-phase of cell cycle and also hinders progression of cells from G1 phase to the S-phase. When inside the cell, cytarabine is converted into the triphosphate derivatives by kinase enzymes to show its cytotoxic effect. The exact mechanism of action of cytarabine triphosphate has not been elucidated but it appears to inhibit DNA polymerase by competing with deoxycytidine triphosphate [24] and thus reduces the cell replication.
Cytarabine is a polar nucleoside and has a short plasma half-life. After three phosphorylation step, cytarabine is converted to cytarabine triphosphate. It has been suggested that cytarabine triphosphate inhibits DNA polymerase by competing with the natural substrate, deoxycytidine triphosphate, resulting in DNA synthesis inhibition. The low bioavailability of cytarabine is created by its low permeability across cell membrane and rapid conversion into inactive 1-β-D-arabinofuranosyluracil (AraU). The drug is rapidly converted into its uridine derivative by deamination of cytosine ring in the presence of cytidine deaminase [25] . Thus, continuous intravenous infusion of higher doses is required to maintain constant plasma level of the drug in 8 to 24 h. The higher doses of cytarabine lead to toxicity on normal organs and side effects [26] . Alternatively, cytarabine is administered by subcutaneous infusion in which peak plasma levels are attained after 20 to 60 min and decrease below steady-state level after 100 min [27] .
Understanding the mechanism of the action and metabolism of cytarabine has allowed many investigations to improve the low bioavailability and stability. These efforts, depending upon formulation and modification, can be divided into two major categories: prodrugs and drug delivery systems. The prodrug strategy for cytarabine involves the chemical modification or introduction of a potentiating group on parent drug while the delivery system involved in physical encapsulation of drug without introduction of any chemical modification on parent drug. The molecules synthesized for prodrug evaluation may have higher therapeutic effect while the delivery system may improve the effect in a particular tissue or organ. Various explored prodrug strategies and potential of delivery systems for cytarabine are discussed.
Cytarabine Prodrugs
Most of the therapeutic drugs have to pass physiological barriers before reaching to the target organ/tissue of action. Many drugs get modified into inactive derivatives during the transportation process. Among the various strategies used to minimize the undesirable metabolism of drug, prodrug approach offers a great promise in retention of pharmacological properties of drugs, improving the drug efficacy, decreasing the toxicity, or reduction in dose of administration.
Prodrugs are defined as pharmacologically inert chemical derivatives that can be converted into the active drug molecules under in vivo physiological conditions through an enzymatically or nonenzymatic process, to exert a therapeutic effect at desired target site. An Ideal prodrug is converted to the original therapeutically active form of drug at target organ and the substituted group is eliminated from the body [28] . Thus, prodrug approach may minimize undesirable toxicity related to the parent drug in non-targeted organs [29, 30] .
Many prodrugs have been developed to improve drug efficacy, absorption, bioavailability, instability, drug delivery, drug specificity, toxicity, membrane transportation, or patient adherence (like poor taste or odor of drug) [31, 32] . Designing of prodrugs generally depends upon many factors including the mechanism of action, enzymatic interaction, lipophilicity, functional groups present on the drug and their lability, and metabolic pathway of drug.
There have been major efforts on the development of cytarabine derivatives to generate compounds with higher therapeutic index for the treatment of leukemia and lymphoma (sections 2.1-2.3). Among the explored strategies, the prodrug strategy of introducing modifications on the parent drug to enhance plasma half-life or delivery to cancer cells is a subject of major interest.
The prodrug design for cytarabine has been explored on the basis of mechanism of action and metabolism of the drug. The deamination of the cytosine base of cytarabine by cytidine deaminase leads to formation of uridine derivative (AraU) and deactivation of the drug. In general, cytarabine prodrugs have been designed either to circumvent its catabolism into AraU or to enhance cellular delivery. Some of the prodrug approaches included designing amino acid-cytarabine, fatty acid-cytarabine, and amino acid-fatty acid-cytarabine derivatives (sections 2.1 and 2.2).
Mechanistically, cytarabine acts as a prodrug itself and is converted intracellularly to cytarabine triphosphate through monophosphate and diphosphate derivatives before generating biological activities. In the process, monophosphorylation is the rate-limiting step in the metabolic conversion to triphosphate form. Alternatively, many phosphate derivatives of cytarabine have been evaluated as prodrugs to improve the cellular uptake of active metabolites (section 2.3).
Amino acid derivatives
Many amino acid and peptide derivatives are known to increase the cellular uptake of the drug molecules. Peptides with both nucleophilic group (-NH 2 ) and electrophilic (-COOH) groups can be used for the conjugation of a large number of drug molecules. Amino acid or peptide attached to a drug can reduce the undesired metabolism by modification of the hydrolytic activity or the steric effect surrounding susceptible functional groups. Cytarabine derivatives substituted with amino acids at 4-amino or 5′-hydroxyl positions have been synthesized and evaluated by different groups as described below.
The amino acid-substituted derivatives of cytarabine at 4-amino position were designed to reduce the metabolism of cytarabine into uridine derivative by blocking the proximity of cytidine deaminase. Derivatization of cytarabine with a single amino acid at amino group reported by Jin et al. [33] involved the protection of hydroxyl groups by tert-butyldimethyl silyl (TBDMS) followed by the conjugation with protected amino acids.
Amino acid derivatives synthesized with arginine, leucine and isoleucine ( Figure 2 ) were evaluated for cellular uptake in Caco-2 cells and were compared with that of cytarabine.
The arginine derivative was shown to have comparable uptake while the leucine and isoleucine derivatives reduced the uptake of drug. They have also compared the concentration dependency cellular uptake of the synthesized derivatives and found a similar uptake for cytarabine and arginine-cytarabine at increased concentrations while leucine-cytarabine and isoleucine-cytarabine derivatives showed less cellular uptake than that of the parent drug at higher concentrations. 
Fatty acid derivatives
The pharmacological properties of drugs depend upon overall surface interactions with medium and can be modulated by variation in the lipophilicity/hydrophilicity ratio. The presence of long fatty acyl chains makes the drug molecules lipophilic [36] . Furthermore, the lipophilic drugs pass across the membrane rapidly and make the drug available for biological action at higher intracellular concentration in target cells. The fatty acid conjugation of the drugs through esterification or amidation leads to formation of ester or amide bond, respectively, with the drug molecule. The approach has two advantages: First, the conjugation protects the functional group. Second, the substitution allows sustained and continuous release of the drug through hydrolysis thus minimizing the side effects at higher doses of drugs.
The prodrug approach using fatty acid derivatization at 5′-OH and 4-NH 2 groups of cytarabine has been evaluated by many research groups. In addition to making the drug more lipophilic, the strategy may also allow the protection of cytarabine from cytidine deaminase enzyme action and thus preventing its metabolism into inactive form Fatty acids-substituted conjugates of cytarabine at 5′-OH showed significantly different behavior than N4 derivatives. Derivatization with different saturated and unsaturated higher fatty acids showed comparable activity to that of cytarabine in different cell lines [38] . Among the derivatives, CP-4055, a fatty acid derivative of cytarabine (ara-C-5′-elaidic acid ester) ( Figure 5 ), facilitated and enhanced cellular accumulation and retention of ara-C in tumor cells. Unlike cytarabine, the cellular uptake of CP-4055 is independent of nucleoside transporters, and is believed to be via passive diffusion through the cellular membrane or an alternative internalization mechanism [39] . CP-4055 is then hydrolyzed intracellularly by esterases to release free cytarabine, which is subsequently phosphorylated to the active triphosphate analog. When compared with cytarabine as a potent inhibitor of DNA synthesis [40] , CP-4055 also transiently inhibits RNA synthesis. Furthermore, the fatty acyl conjugation potentially delayed inactivation to ara-U. CP-4055 is not a substrate for cytidine deaminase. CP-4055 demonstrated cytotoxicity in solid tumor and leukemia cells in vitro and in vivo [41] . CP-4055 was evaluated against a lymphoma cell line with deficient nucleoside transport (5CEM-araC/C8) and was resistant to cytarabine. CP-4055 was able to kill a high proportion of drug-resistant cells by apoptosis [42] . Further studies of CP-4055 in human leukemia and lymphoma HL-60 and U937 cells demonstrated additive or synergistic cytotoxic activity in combination with other anticancer drugs, such as cloretazine, idarubicin, gemcitabine, irinotecan, and topotecan, [43] . The 2′-hydroxyl position of arabinose sugar in cytarabine was further explored for functionalizing with fatty acids. We synthesized and evaluated the 2′-O and 5′-Omyristoyl and 2′,5′-dimyristoyl derivatives ( Figure 6 ). As the cytotoxic mechanism of cytarabine involves phosphorylation of 5′-hydroxyl into triphosphate, the effectiveness of fatty acyl ester derivatives depends on the concentration of the parent drug delivered intracellularly after hydrolysis and availability of 5′-hydroxyl group for phosphorylation [45] . that of cytarabine after 96 h, the sustained-release property may be beneficial.
Phosphate derivatives
The phosphate prodrug approach has been widely used with nucleoside drugs [46] . Nucleosides are converted intracellularly into the monophosphate, diphosphate, and triphosphate derivatives, respectively, before generating biological activities. The monophosphorylation is generally the rate-determining step and thus delivery of monophosphorylated nucleosides that bypass this step is highly desired. Cytarabine is also converted into the triphosphate form before incorporation into nucleic acids. Thus, various phosphate derivatives of cytarabine have been synthesized and evaluated as discussed below.
Lipophilic phosphate prodrugs of cytarabine were designed to contain both the phosphate and lipid (fatty chain) properties. The concept of using lipophilic nucleoside monophosphate ester derivatives of cytarabine was proposed to bypass the first phosphorylation step and circumvent tumor resistance associated with decreased deoxycytidine kinase activity via kinase bypass. Furthermore, it was expected that metabolic degradation by cytidine deaminase to be reduced. Finally, partial masking of the phosphate charge and increased lipophilicity may allow higher intracellular levels of the parent analog [47, 48, 49] .
Initially, it was expected that cleavage of the prodrug moiety was due to the action of phosphodiesterase; however, it was subsequently demonstrated that the release of the parent drug occurs via successive two-carbon degradation via oxidation in peroxisomes [50] . The investigations led to discovery of the stearyl phosphate diester of cytarabine (cytarabine ocfosfate, YNK01) ( Figure 7 ) [51] . Further clinical evaluation of cytarabine ocfosfate showed enhanced stability and higher half-life when compared with cytarabine and showed great promise for oral administration [52, 53, 54] . A phase 1/2 study demonstrated that 15.8% of the total dose was absorbed and metabolized to cytarabine and AraU [55] . Cytarabine ocfosfate was approved in 1992 [56] in Japan by
Nippon Kayaky under license from Yamasa Shoyu for use in patients with adult acute nonlymphocytic leukemia and myelodysplastic syndrome [57] . To compare the hydrolysis of phosphotriester derivatives of nucleosides [58] , three derivatives, cytarabine phosphotriester derivative, AZT phosphate prodrug, and snake venom phosphodiesterase (SVP)-substrate (p-nitrophenyl thymidinyl phosphate),
were tested in presence of SVP (snake venom phosphodiesterase), a representative for the type I phosphodiesterase enzyme family at 37 °C. The hydrolysis led to the formation of the corresponding nucleoside 5′-monophosphate ( Figure 9 ) with half-lives of 4.6 h for cytarabine derivative, 53 min for AZT derivative, and 43 min for p-nitrophenyl thymidinyl phosphate. Thus, 2′-deoxynucleotides were hydrolyzed faster than the corresponding ribonucleotides, and the araC metabolite appeared to be a poor substrate for SVP when compared to AZT or thymidine. These data suggest that a slow hydrolysis to cytarabine monophosphate contributes to reduced antitumor activity.
Phosphoramidate derivatives of cytarabine were also shown to have reduced anticancer activity when compared with cytarabine. For example, a nitrofuran phosphoramidate derivative (Figure 10 ) reported by Tobias et al. showed reduction in anti-proliferative activity when compared to that of cytarabine [59] . Phosphoramidate derivatives of cytarabine metabolite 2-β-D-arabinouridine (AraU) ( Figure 11 ) were evaluated by Mehellou et al. [60] . The rationale for this study was to determine whether phosphorylation of AraU can activate the inactivate metabolite. Thus masked phosphate prodrug was synthesized for intracellular delivery.
The compounds found to have reduced activity when compared with AraU. Hydrolysis studies in cell extract by NMR showed the reduced activity of phosphoramidate derivatives to hydrolysis because of the stability of P-N bond to hydrolysis. In general, the biological activities of synthesized fatty acid, amino acid, and phosphate conjugates depended upon the mechanism and ease of intracellularly released cytarabine or monophosphate derivative. The phosphorylation process occurs on the 5′-OH group of the arabinose sugar. Prodrug strategies that used either the substitution at 4-amine group of cytosine base or the protected 5′-monophosphate derivatives have resulted in compromised activities against various cancers.
Delivery Systems
The drugs, which have poor solubility, low cell permeability, fast metabolism and 
Hydrogels
Hydrogels are biomaterials consisting of a polymer matrix with a high water retention capacity. The hydrogels are capable of encapsulating the hydrophilic drugs.
Sustained release of the drug depends on the polymer matrix constitution. The hydrogels have application as biomaterials since they have similarity in physical properties, such as water contents, soft consistency and low interfacial tension, to those of natural tissues in biological systems [65] . The encapsulation of hydrophilic drugs such as nucleoside analogs with hydrogels would be easy and loading could be expected higher compared to other polymers. On the other hand, the strong interaction among the polymer and drug would hinder the release.
Cytarabine has been studied with HEMA (2-hydroxyethyl methacrylate) [66] and HEMA copolymerized with acrylamide [67] . The study showed that the rate and total time of cytarabine release from the copolymer (hydrogels) can be partially modulated by varying the amount of monomer composition and degree of cross linking of the gels.
Even though, hydrogels have not been completely successful for delivery of cytarabine, more studies with different polymer compositions can be used in finding the balanced system for drug encapsulation as well as sustained release.
Liposomes
Liposomes or lipid capsids have been important vehicles for the delivery of a number of drugs [68] . The liposomes are lipophilic systems and can pass the cell membranes easily [69] . They possess unique pharmacokinetic characteristics because of their nanometer size (ranges in mean diameter from 50 to 250 nm) as systemically administered vesicles [70] . These unique characteristic properties allow clearance via the reticuloendothelial system, which leads to a relatively long systemic circulation time, and hepatic and splenic distribution. Furthermore, the liposomes exhibit preferential extravasation and accumulation at the site of solid tumors due to increased endothelial permeability and reduced lymphatic drainage in these tissues [71] . The increased endothelial permeability has been defined as enhanced permeability and retention effect [72] .
Thus, liposomal delivery is a means to modify the pharmacokinetic and pharmacodynamic properties of anticancer agents [73] , improving pharmacological properties, and reducing or modulating their toxicity profile [74] . Polar drugs once encapsulated inside the liposomes are transported across the membranes by facilitated mechanism of liposome capsid. Liposomal cytarabine formulation has been studied with different liposomal compositions and hybrid systems with polymers [75] .
The cytarabine encapsulated liposome has been studied with thermosensitive hydrogels [76] . The hydrogel was based on the biodegradable chitosan and β-glycerophosphate (C-GP) that are thermosensitive and act as a thermal trigger to regulate the drug release from encapsulation. Combining of liposomes with C-GP hydrogel system gave the advantages of more sustained release of cytarabine along with a higher stability of the hydrogel-liposome system compared to liposome alone.
The investigators suggest hydrogel system is appropriate for controlled and sustained release of cytarabine.
Cytarabine crosses the blood-brain barrier only to a limited extent after rapid i.v. cytarabine. On the other hand, the liposomal formulation showed higher cytotoxicity in cytarabine resistant cell line compared to that of parent cytarabine [85] . The cellular uptake of liposomal cytarabine derivative was found to be five times more than cytarabine [86] . Similarly among other derivatives of cytarabine N4-octadecyl cytarabine also showed a similar behavior. After intravenous injection, the liposomal formulation showed longer plasma half-life compared to cytarabine [87, 88] .
Nanoparticles
Nanometer size particles have higher delivery through enhanced permeability to the tumor sites [89] . Drugs attached or encapsulated are delivered at higher concentrations to the site of action and are protected from fast excretion [90] . The polymeric nanoparticles have been extensively investigated for the delivery of various drugs [91, 92] .
Rukmani et al. investigated the methacrylic acid polymeric nanoparticles encapsulation of cytarabine [93] . Detailed morphological analysis of nanoparticles and further in vivo study of hematological parameters after administering CTH nanoparticles continuously for 9 days to tumor bearing mice showed improvement in lifespan of leukemia mice by the formulation when compared to cytarabine alone. The nanoparticular cytarabine formulation was able to restore the altered physiological parameters of leukemic mice to the normal levels and found to have improved pharmacokinetics profile and prolonged the lifespan of mice with increased white blood cells count that make the nanoparticle a potential carrier for the cytarabine.
Other Delivery systems
Among other systems that can serve as delivery vehicles, the natural or artificial polymers/molecules that are biocompatible have been evaluated to improve the delivery of the drug. Some systems include chitosan [94] and niosome vesicles [95] of tween-20
and tween-80 [96, 97] . With these systems little success has been made in getting the final applicable system because of insufficient release of the drug from the conjugates.
In conclusion, among the delivery systems evaluated for application of cytarabine, liposomal formulation has been successful in increasing the half-life and found application in treatment of lymphomatous meningitis. The other systems have shown promising improvement in delivery and require more systemic study for final application.
Conclusion
Cytarabine, a polar nucleoside antileukemia drug with limited plasma stability and cell permeability, has been extensively evaluated by using prodrug and delivery prodrugs and delivery systems with optimal biological activity and delivery. Furthermore, a combination of using an optimal cytarabine prodrug with an appropriate delivery system or using cytarabine or cytarabine prodrugs in conjunction with different anticancer regimens and/or delivery systems may be needed to explore further applications of these strategies in anticancer research.
Expert Opinion
The concept of prodrug has been successfully used in improving the delivery, stability and pharmacological properties of drugs. The prodrug design is based on direct molecular changes on the drug to generate a dormant compound with appropriate physicochemical properties and desired biological activities. In case of nucleoside analogs, the prodrug designing concept is also used to bypass rate-limiting metabolic process by delivering nucleotides. It is not always easy to predict whether the dormant prodrug will be successful in generating desired properties. As shown with many designs for cytarabine prodrugs, modulating higher stability and better release in target tissues still remain a major challenge. Designing diverse number of prodrugs has allowed the discovery of compounds with optimal stability and release properties. Less research has been carried out on conjugation of cytarabine with hydroxyl groups at 2′ and 3′ positions. It appears that substitution at 5′-position with fatty acids alone is beneficial in generating higher lipophilicity and cellular uptake, but may slow down the metabolic phosphorylation of cytarabine. Alternatively, it may be possible to design prodrugs with masked phosphate at 5′-position and lipophilic chains at 2′ or 3′
positions. It remains to be seen whether this strategy can combine the benefits of both approaches.
Owing to limited cellular uptake of cytarabine, noncovalent methods using delivery systems or vehicles were expected to show great promise. These strategies will protect the chemical integrity of cytarabine and the compound is delivered in an intact form. The encapsulation into protected sheaths like polymers, liposomes, hydrogels, and niosomes were expected to provide advantage of membrane transportation and continuous availability in the plasma over time. Among the evaluated delivery systems, the liposomal formulation was successful in enhancing the cytarabine half-life and treatment of lymphomatous meningitis. The hydrogels and niosomes were able to entrap polar cytarabine but the release from these systems remained slow due to strong interaction of drug with the sheath. The future studies need to focus on more optimization of delivery sheaths particularly hydrogel surfaces and nanoparticles to generate controlled or sustained release and appropriate balance of encapsulation and release properties.
It remains to be determined whether an optimal cytarabine prodrug or those under evaluations (e.g., Elacyt TM ) can be combined with promising delivery systems such as liposomes. Furthermore, cytarabine is also used in combination with other anticancer drugs in treatment of patients. Further studies are required to determine whether combination of cytarabine prodrugs with other anticancer agents or using anticancer cocktails containing cytarabine prodrug or cytarabine with an appropriate delivery system can have any beneficial therapeutic effect in treatment of cancer patients.
In summary, design of cytarabine prodrug derivatives and use of delivery systems have generated prodrugs or formulations that have optimal anticancer activity, stability, or delivery. The exploration of inactive prodrugs or not optimal delivery systems provided deep understanding of the underlying factors responsible for inactivity or incompatibility in formulation that led to the development of first generation of products approved by FDA. Further improvement in design, modification in the drug molecule, or delivery sheath may lead to the second generation of compounds with broader applications. The same path may inspire the investigators to design more optimized anticancer nucleosides and other anticancer agents using the knowledge gained here.
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